Abnova (Taiwan) Corporation (4133.TW)
TWD 24.95
(3.31%)
TWD 24.95
(3.31%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.6 Million TWD | -29.44% |
| 2022 | 3.68 Million TWD | 558.21% |
| 2021 | 560 Thousand TWD | -89.44% |
| 2020 | 5.3 Million TWD | -22.29% |
| 2019 | 6.82 Million TWD | 1827.4% |
| 2018 | 354 Thousand TWD | 22.07% |
| 2017 | 290 Thousand TWD | -43.58% |
| 2016 | 514 Thousand TWD | 0.0% |
| 2015 | - TWD | 0.0% |
| 2014 | - TWD | 0.0% |
| 2013 | - TWD | 0.0% |
| 2012 | - TWD | 0.0% |
| 2011 | - TWD | 0.0% |
| 2010 | - TWD | -100.0% |
| 2009 | 744 Thousand TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 2.78 Million TWD | 0.0% |
| 2024 Q2 | 2.41 Million TWD | 0.0% |
| 2023 Q3 | 2.85 Million TWD | -8.08% |
| 2023 Q2 | 3.1 Million TWD | -7.48% |
| 2023 Q4 | 2.6 Million TWD | -8.86% |
| 2023 Q1 | 3.35 Million TWD | -8.95% |
| 2023 FY | 2.6 Million TWD | -29.44% |
| 2022 Q3 | 4.05 Million TWD | -8.3% |
| 2022 FY | 3.68 Million TWD | 558.21% |
| 2022 Q4 | 3.68 Million TWD | -9.1% |
| 2022 Q2 | 4.42 Million TWD | 695.32% |
| 2022 Q1 | 556 Thousand TWD | -0.71% |
| 2021 Q2 | 2.81 Million TWD | -34.8% |
| 2021 Q4 | 560 Thousand TWD | -66.86% |
| 2021 Q1 | 4.31 Million TWD | -18.6% |
| 2021 FY | 560 Thousand TWD | -89.44% |
| 2021 Q3 | 1.69 Million TWD | -39.94% |
| 2020 Q3 | 5.07 Million TWD | 29.9% |
| 2020 FY | 5.3 Million TWD | -22.29% |
| 2020 Q1 | 5.31 Million TWD | -22.16% |
| 2020 Q2 | 3.9 Million TWD | -26.45% |
| 2020 Q4 | 5.3 Million TWD | 4.49% |
| 2019 FY | 6.82 Million TWD | 1827.4% |
| 2019 Q4 | 6.82 Million TWD | 21.73% |
| 2019 Q3 | 5.6 Million TWD | -26.18% |
| 2019 Q1 | 9.64 Million TWD | 2624.29% |
| 2019 Q2 | 7.59 Million TWD | -21.27% |
| 2018 FY | 354 Thousand TWD | 22.07% |
| 2018 Q2 | 340 Thousand TWD | 9.68% |
| 2018 Q3 | 335 Thousand TWD | -1.47% |
| 2018 Q1 | 310 Thousand TWD | 6.9% |
| 2018 Q4 | 354 Thousand TWD | 5.67% |
| 2017 Q4 | 290 Thousand TWD | 0.0% |
| 2017 Q2 | - TWD | -100.0% |
| 2017 FY | 290 Thousand TWD | -43.58% |
| 2017 Q1 | 534 Thousand TWD | 3.89% |
| 2017 Q3 | - TWD | 0.0% |
| 2016 Q3 | - TWD | 0.0% |
| 2016 FY | 514 Thousand TWD | 0.0% |
| 2016 Q4 | 514 Thousand TWD | 0.0% |
| 2016 Q2 | - TWD | 0.0% |
| 2016 Q1 | - TWD | 0.0% |
| 2015 FY | - TWD | 0.0% |
| 2015 Q4 | - TWD | 0.0% |
| 2015 Q3 | - TWD | 0.0% |
| 2015 Q2 | - TWD | 0.0% |
| 2015 Q1 | - TWD | 0.0% |
| 2014 Q3 | - TWD | 0.0% |
| 2014 FY | - TWD | 0.0% |
| 2014 Q4 | - TWD | 0.0% |
| 2014 Q2 | - TWD | 0.0% |
| 2014 Q1 | - TWD | 0.0% |
| 2013 Q3 | - TWD | 0.0% |
| 2013 Q4 | - TWD | 0.0% |
| 2013 FY | - TWD | 0.0% |
| 2013 Q1 | - TWD | 0.0% |
| 2013 Q2 | - TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2012 Q4 | - TWD | 0.0% |
| 2012 FY | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 Q1 | - TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q3 | - TWD | 0.0% |
| 2011 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2010 FY | - TWD | -100.0% |
| 2009 FY | 744 Thousand TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | 116.19 Million TWD | 97.762% |
| Sinphar Pharmaceutical Co.,Ltd. | 1.49 Billion TWD | 99.826% |
| Panion & Bf Biotech Inc. | 125.41 Million TWD | 97.926% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 700 Million TWD | 99.628% |
| GenMont Biotech Incorporation | 20.11 Million TWD | 87.067% |
| Adimmune Corporation | 1.91 Billion TWD | 99.864% |
| Tanvex BioPharma, Inc. | 1.56 Billion TWD | 99.834% |
| Polaris Group | 352.96 Million TWD | 99.263% |
| Energenesis Biomedical CO.,LTD. | - TWD | -Infinity% |
| UnicoCell Biomed Co., Ltd. | 68.23 Million TWD | 96.188% |
| PELL Bio-Med Technology Co. Ltd. | 147.46 Million TWD | 98.236% |